Overview

A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension

Status:
Completed
Trial end date:
2020-12-18
Target enrollment:
Participant gender:
Summary
This is a study of the efficacy and safety of JZP-258, an oxybate mixed-salts oral solution being developed as a low sodium alternative product for Xyrem.
Phase:
Phase 3
Details
Lead Sponsor:
Jazz Pharmaceuticals